# A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

> **NCT04483947** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 74 (actual)

## Conditions studied

- Non-alcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** AZD2693
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04483947
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-06
- **Primary completion:** 2023-12-18
- **Final completion:** 2023-12-18
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2024-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04483947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04483947, "A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04483947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*